Oncocytic Tumors in the Thyroid: A Tri-Focal Review – Integrated Cytopathological, Pathological, and Molecular Perspectives

2.

Christofer Juhlin

C

,

Mete

O

,

Baloch

ZW

.

The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading

.

Endocr Relat Cancer

.

2023

;

30

(

2

):

e220293

.

3.

Baloch

ZW

,

Asa

SL

,

Barletta

JA

,

Ghossein

RA

,

Juhlin

CC

,

Jung

CK

, et al.

Overview of the 2022 WHO classification of thyroid neoplasms

.

Endocr Pathol

.

2022

;

33

(

1

):

27

–

63

.

4.

Nesland

JM

,

Sobrinho-Simões

MA

,

Holm

R

,

Sambade

MC

,

Johannessen

JV

.

Hurthle-cell lesions of the thyroid: a combined study using transmission electron microscopy, scanning electron microscopy, and immunocytochemistry

.

Ultrastruct Pathol

.

1985

;

8

(

4

):

269

–

90

.

5.

Asa

SL

,

Mete

O

.

Oncocytic change in thyroid pathology

.

Front Endocrinol

.

2021

;

12

:

678119

.

6.

Canberk

S

,

LiVolsi

VA

,

Baloch

Z

.

Oncocytic lesions of the neuroendocrine system

.

Adv Anat Pathol

.

2014

;

21

(

2

):

69

–

82

.

7.

Montone

KT

,

Baloch

ZW

,

LiVolsi

VA

.

The thyroid Hurthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review

.

Arch Pathol Lab Med

.

2008

;

132

(

8

):

1241

–

50

.

8.

Mete

O

,

Asa

SL

.

Oncocytes, oxyphils, Hurthle, and Askanazy cells: morphological and molecular features of oncocytic thyroid nodules

.

Endocr Pathol

.

2010

;

21

(

1

):

16

–

24

.

9.

Baloch

ZW

,

LiVolsi

VA

.

Oncocytic lesions of the neuroendocrine system

.

Semin Diagn Pathol

.

1999

;

16

(

2

):

190

–

9

.

10.

Canberk

S

,

Griffin

AC

,

Goyal

A

,

Wang

H

,

Montone

K

,

Livolsi

V

, et al.

Oncocytic follicular nodules of the thyroid with or without chronic lymphocytic thyroiditis: an institutional experience

.

CytoJournal

.

2013

;

10

:

2

.

11.

Stegenga

MT

,

Oudijk

L

,

van Velsen

EFS

,

Peeters

RP

,

Medici

M

,

Verburg

FA

, et al.

Impact of reclassification of oncocytic and follicular thyroid carcinoma by the 2022 WHO classification

.

J Clin Endocrinol Metab

.

2024

:

dgae581

.

12.

DeLellis

RA

. In:

Kleihues

P

,

Sobin

LE

, editors.

WHO: Pathology and genetics. Tumours of endocrine organs. WHO classification of tumours

.

Lyon, France

:

IARC Press

;

2004

.

13.

WHO Classification of Tumours of Endocrine Organs

.

WHO/IARC classification of tumours

. 4th 10th ed.

Lyon, France

:

WHO/IARC Press

;

2017

.

14.

Gundry

SR

,

Burney

RE

,

Thompson

NW

,

Lloyd

R

.

Total thyroidectomy for Hurthle cell neoplasm of the thyroid

.

Arch Surg

.

1983

;

118

(

5

):

529

–

32

.

15.

McLeod

MK

,

Thompson

NW

.

Hurthle cell neoplasms of the thyroid

.

Otolaryngol Clin North Am

.

1990

;

23

(

3

):

441

–

52

.

16.

Thompson

NW

,

Dunn

EL

,

Batsakis

JG

,

Nishiyama

RH

.

Hurthle cell lesions of the thyroid gland

.

Surg Gynecol Obstet

.

1974

;

139

(

4

):

555

–

60

.

17.

Stojadinovic

A

,

Ghossein

RA

,

Hoos

A

,

Urist

MJ

,

Spiro

RH

,

Shah

JP

, et al.

Hurthle cell carcinoma: a critical histopathologic appraisal

.

J Clin Oncol

.

2001

;

19

(

10

):

2616

–

25

.

18.

Stojadinovic

A

,

Hoos

A

,

Ghossein

RA

,

Urist

MJ

,

Leung

DHY

,

Spiro

RH

, et al.

Hurthle cell carcinoma: a 60-year experience

.

Ann Surg Oncol

.

2002

;

9

(

2

):

197

–

203

.

19.

Strazisar

B

,

Petric

R

,

Sesek

M

,

Zgajnar

J

,

Hocevar

M

,

Besic

N

.

Predictive factors of carcinoma in 279 patients with Hurthle cell neoplasm of the thyroid gland

.

J Surg Oncol

.

2010

;

101

(

7

):

582

–

6

.

20.

Tallini

G

.

Oncocytic tumours

.

Virchows Arch

.

1998

;

433

(

1

):

5

–

12

.

21.

Tallini

G

,

Carcangiu

ML

,

Rosai

J

.

Oncocytic neoplasms of the thyroid gland

.

Acta Pathol Jpn

.

1992

;

42

(

5

):

305

–

15

.

22.

Poller

DN

,

Megadmi

H

,

Ward

MJA

,

Trimboli

P

.

Hurthle cells on fine-needle aspiration cytology are important for risk assessment of focally PET/CT FDG avid thyroid nodules

.

Cancers

.

2020

;

12

(

12

):

3544

.

23.

Goffredo

P

,

Roman

SA

,

Sosa

JA

.

Hurthle cell carcinoma: a population-level analysis of 3311 patients

.

Cancer

.

2013

;

119

(

3

):

504

–

11

.

24.

Bischoff

LA

,

Ganly

I

,

Fugazzola

L

,

Buczek

E

,

Faquin

WC

,

Haugen

BR

, et al.

Molecular alterations and comprehensive clinical management of oncocytic thyroid carcinoma: a review and multidisciplinary 2023 update

.

JAMA Otolaryngol Head Neck Surg

.

2024

;

150

(

3

):

265

–

72

.

25.

Maximo

V

,

Soares

P

,

Lima

J

,

Cameselle-Teijeiro

J

,

Sobrinho-Simões

M

.

Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors

.

Am J Pathol

.

2002

;

160

(

5

):

1857

–

65

.

26.

Maximo

V

,

Botelho

T

,

Capela

J

,

Soares

P

,

Lima

J

,

Taveira

A

, et al.

Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid

.

Br J Cancer

.

2005

;

92

(

10

):

1892

–

8

.

27.

Gopal

RK

,

Vantaku

VR

,

Panda

A

,

Reimer

B

,

Rath

S

,

To

TL

, et al.

Effectors enabling adaptation to mitochondrial complex I loss in hurthle cell carcinoma

.

Cancer Discov

.

2023

;

13

(

8

):

1904

–

21

.

28.

Thodou

E

,

Canberk

S

,

Schmitt

F

.

Challenges in cytology specimens with hurthle cells

.

Front Endocrinol

.

2021

;

12

:

701877

.

29.

Wong

KS

,

Jo

VY

,

Lowe

AC

,

Faquin

WC

,

Renshaw

AA

,

Shah

AA

, et al.

Malignancy risk for solitary and multiple nodules in Hurthle cell-predominant thyroid fine-needle aspirations: a multi-institutional study

.

Cancer Cytopathol

.

2020

;

128

(

1

):

68

–

75

.

30.

Yang

GC

,

Schreiner

AM

,

Sun

W

.

Can abundant colloid exclude oncocytic (Hurthle cell) carcinoma in thyroid fine needle aspiration? Cytohistological correlation of 127 oncocytic (Hurthle cell) lesions

.

Cytopathology

.

2013

;

24

(

3

):

185

–

93

.

31.

Mijovic

T

,

Rochon

L

,

Gologan

O

,

Hier

MP

,

Black

MJ

,

Young

J

, et al.

Fine-needle aspiration biopsies in the management of indeterminate follicular and Hurthle cell thyroid lesions

.

Otolaryngol Head Neck Surg

.

2009

;

140

(

5

):

715

–

9

.

32.

Wu

HH

,

Clouse

J

,

Ren

R

.

Fine-needle aspiration cytology of Hurthle cell carcinoma of the thyroid

.

Diagn Cytopathol

.

2008

;

36

(

3

):

149

–

54

.

33.

Gonzalez

JL

,

Wang

HH

,

Ducatman

BS

.

Fine-needle aspiration of Hurthle cell lesions. A cytomorphologic approach to diagnosis

.

Am J Clin Pathol

.

1993

;

100

(

3

):

231

–

5

.

34.

Howson

P

,

Kruijff

S

,

Aniss

A

,

Pennington

T

,

Gill

AJ

,

Dodds

T

, et al.

Oxyphil cell parathyroid adenomas causing primary hyperparathyroidism: a clinico-pathological correlation

.

Endocr Pathol

.

2015

;

26

(

3

):

250

–

4

.

35.

Giorgadze

T

,

Stratton

B

,

Baloch

ZW

,

Livolsi

VA

.

Oncocytic parathyroid adenoma: problem in cytological diagnosis

.

Diagn Cytopathol

.

2004

;

31

(

4

):

276

–

80

.

36.

Paker

I

,

Yilmazer

D

,

Yandakci

K

,

Arikok

AT

,

Alper

M

.

Intrathyroidal oncocytic parathyroid adenoma: a diagnostic pitfall on fine-needle aspiration

.

Diagn Cytopathol

.

2010

;

38

(

11

):

833

–

6

.

37.

Rossi

ED

,

Baloch

Z

.

The impact of the 2022 WHO classification of thyroid neoplasms on everyday practice of cytopathology

.

Endocr Pathol

.

2023

;

34

(

1

):

23

–

33

.

38.

Suster

D

,

Ronen

N

,

Giorgadze

T

.

Oncocytic nodular hyperplasia of the thyroid

.

Ann Diagn Pathol

.

2022

;

61

:

152049

.

39.

Landau

MS

,

Nikiforov

YE

,

Ohori

NP

,

Chiosea

SI

.

Impact of molecular testing on detecting mimics of oncocytic neoplasms in thyroid fine-needle aspirates diagnosed as follicular neoplasm of Hurthle cell (oncocytic) type

.

Cancer Cytopathol

.

2021

;

129

(

10

):

788

–

97

.

40.

Gilani

SM

,

Ross

JA

,

Prasad

ML

,

Hammers

L

,

Cai

G

,

Adeniran

AJ

.

Molecular alterations in Hurthle cell neoplasms of thyroid: a fine needle aspiration cytology study with cytology-histology correlation

.

Cancer Cytopathol

.

2021

;

129

(

5

):

363

–

73

.

41.

Andrianus

S

,

Gubbiotti

MA

,

Mandel

SJ

,

Nikiforov

YE

,

Baloch

Z

.

Unraveling the significance of TSHR mutations in indeterminate thyroid cytology specimens

.

Diagn Cytopathol

.

2023

;

51

(

7

):

406

–

13

.

42.

Lee

SK

,

Rho

BH

,

Woo

SK

.

Hurthle cell neoplasm: correlation of gray-scale and power Doppler sonographic findings with gross pathology

.

J Clin Ultrasound

.

2010

;

38

(

4

):

169

–

76

.

43.

Spagnuolo

GM

,

Tierney

HT

,

Laver

NMV

,

Eldeiry

LS

.

A retrospective study of clinicopathologic outcomes of nodules with hurthle cell cytology and the thyroid nodule app (TNAPP) ultrasound recommendations

.

Endocr Pract

.

2022

;

28

(

6

):

593

–

8

.

44.

Nikiforova

MN

,

Mercurio

S

,

Wald

AI

,

Barbi de Moura

M

,

Callenberg

K

,

Santana-Santos

L

, et al.

Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules

.

Cancer

.

2018

;

124

(

8

):

1682

–

90

.

45.

Wong

KS

,

Angell

TE

,

Barletta

JA

,

Krane

JF

.

Hurthle cell lesions of the thyroid: progress made and challenges remaining

.

Cancer Cytopathol

.

2021

;

129

(

5

):

347

–

62

.

46.

Li

S

,

Baloch

ZW

,

Tomaszewski

JE

,

LiVolsi

VA

.

Worrisome histologic alterations following fine-needle aspiration of benign parotid lesions

.

Arch Pathol Lab Med

.

2000

;

124

(

1

):

87

–

91

.

47.

LiVolsi

VA

,

Merino

MJ

.

Worrisome histologic alterations following fine-needle aspiration of the thyroid (WHAFFT)

.

Pathol Annu

.

1994

;

29 (Pt 2)

(

Pt 2

):

99

–

120

.

48.

Bonora

E

,

Porcelli

AM

,

Gasparre

G

,

Biondi

A

,

Ghelli

A

,

Carelli

V

, et al.

Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III

.

Cancer Res

.

2006

;

66

(

12

):

6087

–

96

.

49.

Gasparre

G

,

Porcelli

AM

,

Bonora

E

,

Pennisi

LF

,

Toller

M

,

Iommarini

L

, et al.

Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors

.

Proc Natl Acad Sci U S A

.

2007

;

104

(

21

):

9001

–

6

.

50.

Doerfler

WR

,

Nikitski

AV

,

Morariu

EM

,

Ohori

NP

,

Chiosea

SI

,

Landau

MS

, et al.

Molecular alterations in Hurthle cell nodules and preoperative cancer risk

.

Endocr Relat Cancer

.

2021

;

28

(

5

):

301

–

9

.

51.

Kure

S

,

Ohashi

R

.

Thyroid hurthle cell carcinoma: clinical, pathological, and molecular features

.

Cancers

.

2020

;

13

(

1

):

26

.

52.

Fariduddin

MM

,

Mathias

PM

,

Syed

W

.

Hurthle cell thyroid carcinoma

.

StatPearls

.

Treasure Island (FL)

;

2024

.

53.

Sobrinho-Simoes

MA

,

Nesland

JM

,

Holm

R

,

Sambade

MC

,

Johannessen

JV

.

Hurthle cell and mitochondrion-rich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study

.

Ultrastruct Pathol

.

1985

;

8

(

2–3

):

131

–

42

.

54.

Sherman

S

.

Oncocytic (hurthle cell) thyroid carcinoma

.

StatPearls

.

Treasure Island (FL)

;

2025

.

55.

Gruszczynski

NR

,

Hasan

SS

,

Brennan

AG

,

De La Chapa

J

,

Reddy

AS

,

Martin

DN

, et al.

Oncocytic carcinoma of the thyroid: conclusions from a 20-year patient cohort

.

Head Neck

.

2024

;

46

(

8

):

2042

–

7

.

56.

Fariduddin

MM

,

Syed

W

.

Hurthle cell thyroid carcinoma

.

StatPearls

.

Treasure Island (FL)

;

2021

.

57.

Zhou

X

,

Zheng

Z

,

Chen

C

,

Zhao

B

,

Cao

H

,

Li

T

, et al.

Clinical characteristics and prognostic factors of Hurthle cell carcinoma: a population based study

.

BMC Cancer

.

2020

;

20

(

1

):

407

.

58.

Bishop

JA

,

Wu

G

,

Tufano

RP

,

Westra

WH

.

Histological patterns of locoregional recurrence in Hurthle cell carcinoma of the thyroid gland

.

Thyroid

.

2012

;

22

(

7

):

690

–

4

.

59.

Doghri

R

,

Znaidi

N

,

Blel

A

,

Aloui

R

,

Lahyeni

R

,

Ben Salah

M

, et al.

Thyroid oncocytic neoplasms

.

Tunis Med

.

2018

;

96

(

3

):

219

–

23

.

60.

Geetha

SD

,

Karam

P

,

Ziemba

Y

,

Chau

K

,

Savant

D

,

Rosca

O

, et al.

Correlation of cytologic features with molecular testing of indeterminate oncocytic (hurthle cell) thyroid lesions

.

Diagn Cytopathol

.

2025

;

53

(

3

):

102

–

10

.

61.

Yang

GC

,

Schreiner

AM

,

Sun

W

.

Can abundant colloid exclude oncocytic (Hurthle cell) carcinoma in thyroid fine needle aspiration? Cytohistological correlation of 127 oncocytic (Hurthle cell) lesions

.

Cytopathology

.

2013

;

24

(

3

):

185

–

93

.

62.

Yang

YJ

,

Khurana

KK

.

Diagnostic utility of intracytoplasmic lumen and transgressing vessels in evaluation of Hurthle cell lesions by fine-needle aspiration

.

Arch Pathol Lab Med

.

2001

;

125

(

8

):

1031

–

5

.

63.

Giorgadze

T

,

Rossi

ED

,

Fadda

G

,

Gupta

PK

,

Livolsi

VA

,

Baloch

Z

.

Does the fine-needle aspiration diagnosis of “Hurthle-cell neoplasm/follicular neoplasm with oncocytic features” denote increased risk of malignancy

.

Diagn Cytopathol

.

2004

;

31

(

5

):

307

–

12

.

64.

Ren

Y

,

Kyriazidis

N

,

Faquin

WC

,

Soylu

S

,

Kamani

D

,

Saade

R

, et al.

The presence of hurthle cells does not increase the risk of malignancy in most Bethesda categories in thyroid fine-needle aspirates

.

Thyroid

.

2020

;

30

(

3

):

425

–

31

.

65.

Agarwal

S

,

Bychkov

A

,

Jung

CK

,

Hirokawa

M

,

Lai

CR

,

Hong

S

, et al.

The prevalence and surgical outcomes of Hurthle cell lesions in FNAs of the thyroid: a multi-institutional study in 6 Asian countries

.

Cancer Cytopathol

.

2019

;

127

(

3

):

181

–

91

.

66.

Pu

RT

,

Yang

J

,

Wasserman

PG

,

Bhuiya

T

,

Griffith

KA

,

Michael

CW

.

Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration

.

Diagn Cytopathol

.

2006

;

34

(

5

):

330

–

4

.

67.

Sorrenti

S

,

Trimboli

P

,

Catania

A

,

Ulisse

S

,

De Antoni

E

,

D’Armiento

M

.

Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hurthle cell neoplasm

.

Thyroid

.

2009

;

19

(

4

):

355

–

60

.

68.

Raparia

K

,

Min

SK

,

Mody

DR

,

Anton

R

,

Amrikachi

M

.

Clinical outcomes for “suspicious” category in thyroid fine-needle aspiration biopsy: patient’s sex and nodule size are possible predictors of malignancy

.

Arch Pathol Lab Med

.

2009

;

133

(

5

):

787

–

90

.

69.

Keskek

M

,

Ocak

S

,

Ozalp

N

,

Koc

M

,

Tez

M

.

Clinical significance of Hurthle cells in fine needle aspiration biopsy for multinodular goitre

.

Endocr Regul

.

2010

;

44

(

2

):

65

–

8

.

70.

Roh

MH

,

Jo

VY

,

Stelow

EB

,

Faquin

WC

,

Zou

KH

,

Alexander

EK

, et al.

The predictive value of the fine-needle aspiration diagnosis “suspicious for a follicular neoplasm, hurthle cell type” in patients with hashimoto thyroiditis

.

Am J Clin Pathol

.

2011

;

135

(

1

):

139

–

45

.

71.

Yazici

P

,

Yilmaz

B

,

Bozkurt

E

,

Mihmanli

M

,

Uludag

M

.

Malignancy risk of oncocytic changes in thyroid nodules: who should we offer surgery to

.

Acta Chir Belg

.

2016

;

116

(

1

):

30

–

5

.

72.

Zhang

YW

,

Greenblatt

DY

,

Repplinger

D

,

Bargren

A

,

Adler

JT

,

Sippel

RS

, et al.

Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid

.

Ann Surg Oncol

.

2008

;

15

(

10

):

2842

–

6

.

73.

Sippel

RS

,

Elaraj

DM

,

Khanafshar

E

,

Zarnegar

R

,

Kebebew

E

,

Duh

QY

, et al.

Tumor size predicts malignant potential in Hürthle cell neoplasms of the thyroid

.

World J Surg

.

2008

;

32

(

5

):

702

–

7

.

74.

Kim

TH

,

Lim

JA

,

Ahn

HY

,

Lee

EK

,

Min

HS

,

Won Kim

K

, et al.

Tumor size and age predict the risk of malignancy in Hürthle cell neoplasm of the thyroid and can therefore guide the extent of initial thyroid surgery

.

Thyroid

.

2010

;

20

(

11

):

1229

–

34

.

75.

Renshaw

A

.

Hurthle cell carcinoma is a better gold standard than Hurthle cell neoplasm for fine-needle aspiration of the thyroid: defining more consistent and specific cytologic criteria

.

Cancer (Cancer Cytopathol

.

2002

;

96

(

5

):

261

–

6

.

76.

Volante

M

,

Collini

P

,

Nikiforov

YE

,

Sakamoto

A

,

Kakudo

K

,

Katoh

R

, et al.

Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach

.

Am J Surg Pathol

.

2007

;

31

(

8

):

1256

–

64

.

77.

Dettmer

M

,

Schmitt

A

,

Steinert

H

,

Moch

H

,

Komminoth

P

,

Perren

A

.

Poorly differentiated oncocytic thyroid carcinoma--diagnostic implications and outcome

.

Histopathology

.

2012

;

60

(

7

):

1045

–

51

.

78.

Bai

S

,

Baloch

ZW

,

Samulski

TD

,

Montone

KT

,

LiVolsi

VA

.

Poorly differentiated oncocytic (hurthle cell) follicular carcinoma: an institutional experience

.

Endocr Pathol

.

2015

;

26

(

2

):

164

–

9

.

79.

Nakaguro

M

,

Faquin

WC

,

Baloch

ZW

,

Cantley

RL

,

Compton

ML

,

Ely

KA

, et al.

Fine needle aspiration of salivary gland carcinomas with high-grade transformation: a multi-institutional study of 22 cases and review of the literature

.

Cancer Cytopathol

.

2021

;

129

(

4

):

318

–

25

.

80.

Tondi Resta

I

,

Gubbiotti

MA

,

Montone

KT

,

Livolsi

VA

,

Baloch

ZW

.

Differentiated high grade thyroid carcinomas: diagnostic consideration and clinical features

.

Hum Pathol

.

2024

;

144

:

53

–

60

.

81.

Torous

VF

,

Jitpasutham

T

,

Baloch

Z

,

Cantley

RL

,

Kerr

DA

,

Liu

X

, et al.

Cytologic features of differentiated high-grade thyroid carcinoma: a multi-institutional study of 40 cases

.

Cancer Cytopathol

.

2024

;

132

(

8

):

525

–

36

.

82.

Landa

I

,

Ibrahimpasic

T

,

Boucai

L

,

Sinha

R

,

Knauf

JA

,

Shah

RH

, et al.

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

.

J Clin Investig

.

2016

;

126

(

3

):

1052

–

66

.

83.

Canberk

S

,

Onenerk

M

,

Gunes

P

,

Sayman

E

,

Kilicoglu

G

.

Oncocytic variant of medullary thyroid carcinoma

.

Endocr Pathol

.

2015

;

26

(

4

):

320

–

3

.

84.

Onenerk

M

,

Canberk

S

,

Gunes

P

,

Erkan

M

,

Kilicoglu

GZ

.

Oncocytic variant of poorly differentiated thyroid carcinoma: “Is diagnosis possible by fine-needle aspiration

.

CytoJournal

.

2016

;

13

:

23

.

85.

Anwar

F

.

The phenotype of Hurthle and Warthin-like papillary thyroid carcinomas is distinct from classic papillary carcinoma as to the expression of retinoblastoma protein and E2F-1 transcription factor

.

Appl Immunohistochem Mol Morphol

.

2003

;

11

(

1

):

20

–

7

.

86.

Apel

RL

,

Asa

SL

,

LiVolsi

VA

.

“Warthin-like tumor” of the thyroid

.

Am J Surg Pathol

.

1995

;

19

(

7

):

810

–

4

.

87.

Asa

SL

.

My approach to oncocytic tumours of the thyroid

.

J Clin Pathol

.

2004

;

57

(

3

):

225

–

32

.

88.

Hong

JH

,

Yi

HS

,

Yi

S

,

Kim

HW

,

Lee

J

,

Kim

KS

.

Implications of oncocytic change in papillary thyroid cancer

.

Clin Endocrinol

.

2016

;

85

(

5

):

797

–

804

.

89.

Apel

RL

,

Asa

SL

,

LiVolsi

VA

.

“Warthin-like tumor” of the thyroid

.

Am J Surg Pathol

.

1995

;

19

(

7

):

810

–

4

.

90.

Baloch

ZW

,

LiVolsi

VA

.

Warthin-like papillary carcinoma of the thyroid

.

Arch Pathol Lab Med

.

2000

;

124

(

8

):

1192

–

5

.

91.

Ahn

J

,

Jin

M

,

Kim

WG

,

Kim

TY

,

Kim

WB

,

Shong

YK

, et al.

Limitations of fine-needle aspiration and core needle biopsies in the diagnosis of tall cell variant of papillary thyroid carcinoma

.

Clin Endocrinol

.

2023

;

98

(

1

):

110

–

6

.

92.

Ghossein

RA

,

Leboeuf

R

,

Patel

KN

,

Rivera

M

,

Katabi

N

,

Carlson

DL

, et al.

Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications

.

Thyroid

.

2007

;

17

(

7

):

655

–

61

.

93.

Liu

Z

,

Zeng

W

,

Chen

T

,

Guo

Y

,

Zhang

C

,

Liu

C

, et al.

A comparison of the clinicopathological features and prognoses of the classical and the tall cell variant of papillary thyroid cancer: a meta-analysis

.

Oncotarget

.

2017

;

8

(

4

):

6222

–

32

.

94.

Berho

M

,

Suster

S

.

The oncocytic variant of papillary carcinoma of the thyroid: a clinicopathologic study of 15 cases

.

Hum Pathol

.

1997

;

28

(

1

):

47

–

53

.

95.

Carr

AA

,

Yen

TWF

,

Ortiz

DI

,

Hunt

BC

,

Fareau

G

,

Massey

BL

, et al.

Patients with oncocytic variant papillary thyroid carcinoma have a similar prognosis to matched classical papillary thyroid carcinoma controls

.

Thyroid

.

2018

;

28

(

11

):

1462

–

7

.

96.

Spaulding

SL

,

Ho

R

,

Everest

S

,

Chai

RL

.

The role of molecular testing in the diagnosis of medullary thyroid cancer: a case report of oncocytic medullary thyroid carcinoma and review of the literature

.

Am J Otolaryngol

.

2020

;

41

(

1

):

102312

.

97.

Sams

SB

,

Tompkins

KD

,

Mayson

S

,

Raeburn

CD

,

Mehrotra

S

.

Oncocytic variant of medullary thyroid carcinoma; a rare tumor with numerous diagnostic mimics by fine needle aspiration

.

Diagn Cytopathol

.

2017

;

45

(

12

):

1148

–

52

.

98.

Parampalli Srinivas

S

,

Das

J

,

Monappa

V

.

Oncocytic variant of medullary thyroid carcinoma-A case report

.

Iran J Pathol

.

2019

;

14

(

1

):

83

–

7

.

99.

Tranchida

P

,

Estigarribia

J

,

Sethi

S

,

Giorgadze

T

.

Cytologic diagnosis of recurrent medullary thyroid carcinoma with oncocytic change twenty-one years post-thyroidectomy: case report and review of the literature

.

Diagn Cytopathol

.

2011

;

39

(

9

):

641

–

6

.

100.

Sala

TD

,

Mureşan

S

,

Roman

R

,

Lazăr

A

,

Ion

R

,

Paşcanu

I

.

Hypercalcaemic crisis due to primary hyperparathyroidism: report of two cases

.

J Crit Care Med

.

2019

;

5

(

1

):

34

–

9

.

101.

de Koster

EJ

,

Corver

WE

,

de Geus-Oei

LF

,

Oyen

WJG

,

Ruano

D

,

Schepers

A

, et al.

A clinically applicable molecular classification of oncocytic cell thyroid nodules

.

Endocr Relat Cancer

.

2023

;

30

(

9

):

e230047

.

102.

Gopal

RK

,

Kübler

K

,

Calvo

SE

,

Polak

P

,

Livitz

D

,

Rosebrock

D

, et al.

Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hürthle cell carcinoma

.

Cancer Cell

.

2018

;

34

(

2

):

242

–

55. e5

.

103.

Frank

AR

,

Li

V

,

Shelton

SD

,

Kim

J

,

Stott

GM

,

Neckers

LM

, et al.

Mitochondrial-encoded complex I impairment induces a targetable dependency on aerobic fermentation in hurthle cell carcinoma of the thyroid

.

Cancer Discov

.

2023

;

13

(

8

):

1884

–

903

.

104.

Corver

WE

,

van Wezel

T

,

Molenaar

K

,

Schrumpf

M

,

van den Akker

B

,

van Eijk

R

, et al.

Near-haploidization significantly associates with oncocytic adrenocortical, thyroid, and parathyroid tumors but not with mitochondrial DNA mutations

.

Genes Chromosomes Cancer

.

2014

;

53

(

10

):

833

–

44

.

105.

Corver

WE

,

Ruano

D

,

Weijers

K

,

den Hartog

WCE

,

van Nieuwenhuizen

MP

,

de Miranda

N

, et al.

Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma

.

PLoS One

.

2012

;

7

(

6

):

e38287

.

106.

Ganly

I

,

Makarov

V

,

Deraje

S

,

Dong

Y

,

Reznik

E

,

Seshan

V

, et al.

Integrated genomic analysis of hurthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes

.

Cancer Cell

.

2018

;

34

(

2

):

256

–

70 e5

.

107.

Hellgren

LS

,

Stenman

A

,

Jatta

K

,

Condello

V

,

Larsson

C

,

Zedenius

J

, et al.

Catching the silent culprits: TERT promoter mutation screening of minimally invasive follicular and oncocytic thyroid carcinoma in clinical practice

.

Endocr Pathol

.

2024

;

35

(

4

):

411

–

8

.

108.

Wang

X

,

Liu

Y

,

Chen

L

,

Zhang

J

,

Jiang

R

,

Zhang

L

, et al.

Oncocytic cell carcinoma of the thyroid with TERT promoter mutation presenting as asphyxia in an elderly: a case report

.

Front Endocrinol

.

2024

;

15

:

1349114

.

109.

Ganly

I

,

Ricarte Filho

J

,

Eng

S

,

Ghossein

R

,

Morris

LGT

,

Liang

Y

, et al.

Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy

.

J Clin Endocrinol Metab

.

2013

;

98

(

5

):

E962

–

72

.

110.

Maxwell

EL

,

Palme

CE

,

Freeman

J

.

Hurthle cell tumors: applying molecular markers to define a new management algorithm

.

Arch Otolaryngol Head Neck Surg

.

2006

;

132

(

1

):

54

–

8

.

111.

Raghunathan

R

,

Longstaff

XR

,

Hughes

EG

,

Li

SJ

,

Sant

VR

,

Tseng

CH

, et al.

Diagnostic performance of molecular testing in indeterminate (Bethesda III and IV) thyroid nodules with Hurthle cell cytology

.

Surgery

.

2024

;

175

(

1

):

221

–

7

.

112.

Belaiche

A

,

Morand

GB

,

Turkdogan

S

,

Kang

ES

,

Forest

VI

,

Pusztaszeri

MP

, et al.

Molecular markers in follicular and oncocytic thyroid carcinomas: clinical application of molecular genetic testing

.

Curr Oncol

.

2024

;

31

(

10

):

5919

–

28

.

113.

Nikiforov

YE

,

Steward

DL

,

Robinson-Smith

TM

,

Haugen

BR

,

Klopper

JP

,

Zhu

Z

, et al.

Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules

.

J Clin Endocrinol Metab

.

2009

;

94

(

6

):

2092

–

8

.

114.

Moses

W

,

Weng

J

,

Sansano

I

,

Peng

M

,

Khanafshar

E

,

Ljung

BM

, et al.

Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy

.

World J Surg

.

2010

;

34

(

11

):

2589

–

94

.

115.

Ohori

NP

,

Nikiforova

MN

,

Schoedel

KE

,

LeBeau

SO

,

Hodak

SP

,

Seethala

RR

, et al.

Contribution of molecular testing to thyroid fine-needle aspiration cytology of “follicular lesion of undetermined significance/atypia of undetermined significance”

.

Cancer Cytopathol

.

2010

;

118

(

1

):

17

–

23

.

116.

Giordano

TJ

,

Beaudenon-Huibregtse

S

,

Shinde

R

,

Langfield

L

,

Vinco

M

,

Laosinchai-Wolf

W

, et al.

Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens

.

Hum Pathol

.

2014

;

45

(

7

):

1339

–

47

.

117.

Eszlinger

M

,

Piana

S

,

Moll

A

,

Bösenberg

E

,

Bisagni

A

,

Ciarrocchi

A

, et al.

Molecular testing of thyroid fine-needle aspirations improves presurgical diagnosis and supports the histologic identification of minimally invasive follicular thyroid carcinomas

.

Thyroid

.

2015

;

25

(

4

):

401

–

9

.

118.

Labourier

E

,

Shifrin

A

,

Busseniers

AE

,

Lupo

MA

,

Manganelli

ML

,

Andruss

B

, et al.

Molecular testing for miRNA, mRNA, and DNA on fine-needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology

.

J Clin Endocrinol Metab

.

2015

;

100

(

7

):

2743

–

50

.

119.

Carty

SE

,

Ohori

NP

,

Hilko

DA

,

McCoy

KL

,

French

EK

,

Manroa

P

, et al.

The clinical utility of molecular testing in the management of thyroid follicular neoplasms (Bethesda IV nodules)

.

Ann Surg

.

2020

;

272

(

4

):

621

–

7

.

120.

Welschmeyer

A

,

Kligerman

M

,

Noel

J

.

Management of indeterminate thyroid nodules: a model comparing surgery, molecular testing, and observation

.

Otolaryngol Head Neck Surg

.

2024

;

171

(

5

):

1349

–

54

.

121.

Lastra

RR

,

Pramick

MR

,

Crammer

CJ

,

LiVolsi

VA

,

Baloch

ZW

.

Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience

.

Cancer Cytopathol

.

2014

;

122

(

10

):

737

–

44

.

122.

Parajuli

S

,

Jug

R

,

Ahmadi

S

,

Jiang

XS

.

Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules

.

Diagn Cytopathol

.

2019

;

47

(

11

):

1177

–

83

.

123.

Harrell

RM

,

Bimston

DN

.

Surgical utility of Afirma: effects of high cancer prevalence and oncocytic cell types in patients with indeterminate thyroid cytology

.

Endocr Pract

.

2014

;

20

(

4

):

364

–

9

.

124.

Sacks

WL

,

Bose

S

,

Zumsteg

ZS

,

Wong

R

,

Shiao

SL

,

Braunstein

GD

, et al.

Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy

.

Cancer

.

2016

;

124

(

10

):

722

–

8

.

125.

Krane

JF

,

Cibas

ES

,

Endo

M

,

Marqusee

E

,

Hu

MI

,

Nasr

CE

, et al.

The Afirma Xpression Atlas for thyroid nodules and thyroid cancer metastases: insights to inform clinical decision-making from a fine-needle aspiration sample

.

Cancer Cytopathol

.

2020

;

128

(

7

):

452

–

9

.

126.

Loncar

I

,

van Velsen

EFS

,

Massolt

ET

,

van Kemenade

FJ

,

van Engen-van Grunsven

ACH

,

van Hemel

BM

, et al.

European experience with the Afirma Gene Expression Classifier for indeterminate thyroid nodules: a clinical utility study in The Netherlands

.

Head Neck

.

2023

;

45

(

9

):

2227

–

36

.

127.

Vardarli

I

,

Tan

S

,

Görges

R

,

Krämer

BK

,

Herrmann

K

,

Brochhausen

C

.

Diagnostic accuracy of Afirma gene expression classifier, Afirma gene sequencing classifier, ThyroSeq v2 and ThyroSeq v3 for indeterminate (Bethesda III and IV) thyroid nodules: a meta-analysis

.

Endocr Connect

.

2024

;

13

(

7

):

e240170

.

128.

Nasr

CE

,

Andrioli

M

,

Endo

M

,

Harrell

RM

,

Livhits

MJ

,

Osakwe

I

, et al.

Real-world performance of the afirma genomic sequencing classifier (GSC)-A meta-analysis

.

J Clin Endocrinol Metab

.

2023

;

108

(

6

):

1526

–

32

.

129.

Kandil

E

,

Metz

TA

,

Issa

PP

,

Aboueisha

M

,

Omar

M

,

Attia

AS

, et al.

Diagnostic performance of afirma and interpace diagnostics genetic testing in indeterminate thyroid nodules: a single center study

.

Cancers

.

2023

;

15

(

7

):

2098

.

130.

Lupo

MA

,

Walts

AE

,

Sistrunk

JW

,

Giordano

TJ

,

Sadow

PM

,

Massoll

N

, et al.

Multiplatform molecular test performance in indeterminate thyroid nodules

.

Diagn Cytopathol

.

2020

;

48

(

12

):

1254

–

64

.

131.

Zhang

M

,

Hu

X

,

Liu

L

,

Wang

Y

,

Jiang

J

,

Li

H

, et al.

Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules

.

Medicine

.

2024

;

103

(

4

):

e35960

.

132.

Walsh

PS

,

Wilde

JI

,

Tom

EY

,

Reynolds

JD

,

Chen

DC

,

Chudova

DI

, et al.

Analytical performance verification of a molecular diagnostic for cytology-indeterminate thyroid nodules

.

J Clin Endocrinol Metab

.

2012

;

97

(

12

):

E2297

–

306

.